Immunate S/D (Human Coagulation Factor Viii, Human Von Willebrand Factor)

Human Coagulation Factor VIII and Human von Willebrand Factor, the active ingredient in Immunate S/D, is a coagulation factor replacement presented as a solution for injection for intravenous use. It treats hemophilia A and von Willebrand disease in patients with deficient clotting proteins.

GNH USA supplies Immunate S/D as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and clinics worldwide.

Immunate S/D is used to replace deficient clotting factors in the intrinsic coagulation pathway for bleeding disorders. - Hemophilia A: provides factor VIII to restore clot formation and reduce bleeding episodes. - von Willebrand disease: supplies von Willebrand factor to improve platelet adhesion and stabilize factor VIII, controlling mucosal and surgical bleeding. - Perioperative management in hemophilia A or von Willebrand disease: achieves hemostasis during surgery or invasive procedures.

Adverse reactions to Immunate S/D may vary in frequency and severity.

Common Side Effects: - Fever: mild temperature elevation after infusion. - Headache: transient cranial discomfort. - Nausea: occasional feeling of sickness. - Injection site pain: localized discomfort at the IV site.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Development of inhibitors: neutralizing antibodies against factor VIII that reduce efficacy. - Thromboembolic events: formation of abnormal clots in veins or arteries.

When using Immunate S/D, several precautions should be observed to ensure safety and efficacy. - Assess inhibitor status: test for pre‑existing antibodies against factor VIII before initiating therapy. - Monitor for allergic reactions: observe patients during and after infusion for signs of hypersensitivity. - Adjust dose in renal or hepatic impairment: consider individual patient factors when determining infusion volume. - Avoid concurrent use with high‑dose pro‑coagulants: may increase risk of thrombosis. - Pregnancy and lactation: use only if clearly needed and after risk‑benefit assessment. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Immunate S/D can interact with other medicines, affecting clotting balance or immune response.

Major Interactions (Avoid): - Concurrent high‑dose activated pro‑coagulants (e.g., recombinant factor VIIa): may precipitate thrombotic complications. - Antifibrinolytic agents (e.g., tranexamic acid) in excessive doses: increase risk of clot formation.

Moderate Interactions (Monitor Closely): - Immunosuppressants (e.g., rituximab): may alter inhibitor development. - Antibiotics that affect renal function (e.g., aminoglycosides): require monitoring of infusion tolerance. - Vaccines administered shortly before or after infusion: may affect immune response.